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PURPOSE. To describe clinical pharmacist interventions across a range of critical care units (CCUs) 
throughout the United Kingdom (UK). To identify CCU medication error rate, prescription optimisation and to 
identify the type and impact of each intervention in the prevention of harm and improvement of patient therapy.  
  
 MATERIALS AND METHODS. A prospective observational study was undertaken in 21 UK CCUs from 5-
18
th
 Nov 2012. A data collection web portal was designed where the specialist critical care pharmacist (SCCP)  
reported all interventions at their site.  Each intervention was classified as either: medication error, optimisation 
or consult. In addition, a clinical impact scale was used to code the interventions. Interventions were scored as 
low, moderate, high impact and life saving. The final coding was moderated by blinded independent 
multidisciplinary trialists. 
RESULTS. 20,517 prescriptions were reviewed with 3,294 interventions recorded during the weekdays. This 
resulted in an overall intervention rate of 16.1%: 6.8% were classified as medication errors, 8.3 % optimisations 
and 1.0% consults. The interventions were classified as: low impact (34.0%), moderate impact (46.7%) high 
impact (19.3%) and one case was life saving. Almost three-quarters of interventions were to optimise the 
effectiveness of and  improve safety of  pharmacotherapy. 
CONCLUSIONS. This observational study demonstrated that both medication error resolution and pharmacist 
led optimisation rates were substantial. Almost 1 in 6 prescriptions required an intervention from the clinical 
pharmacist. The error rate was slightly lower than an earlier UK prescribing error study (EQUIP). Two thirds of 
the interventions were of moderate to high impact.  
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Introduction 
 
The critically ill patient is at risk of medicines-related adverse events [1], drug interactions and on some 
occasions inadequate therapy [2]. This risk can be exacerbated by the presence of organ failure or by supportive 
therapies such as renal replacement therapy. Consequently, interventions to reduce medication errors and 
optimise therapy are an essential component of patient care. These include electronic prescribing, smart infusion 
pumps, medicines reconciliation, clinical guidelines and services normally led by a specialist critical care 
pharmacist (SCCP) [3]. Improving the safety and efficacy of medication therapy in critical care patients is the 
cornerstone of SCCP activity. Since the first reports of clinical pharmacist interventions in critical care in the 
mid-1980s [4], there has been a gradual progression from those focused on financial savings in medicine use, to 
reducing medication errors and more recently to the optimisation of medication therapy [5]. Clinical pharmacists 
have been reported to improve medicines-related patient outcomes in the use of sedation [6], antimicrobial 
therapy [7], therapeutic drug monitoring [8]  and management of thromboembolism/ infarction [9]. Medicines 
optimisations by addition or adjustment of pharmacotherapy are becoming more dominant practices [10, 11]. 
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Furthermore, proactive interventions, such as SCCP initiated recommendations made as part of their individual 
patient review or attendance in multidisciplinary ward rounds, now comprise the majority of medicines 
interventions made by SCCPs [11, 12]. 
 
 
Despite almost three decades of reports of clinical pharmacist in CCU activity, many important questions 
remain unanswered. Firstly, the current evidence-base is composed of mainly North American reports and 
focuses on single centres and often specific intervention types, e.g. drug-drug interactions [13] or adverse drug 
events [14]. As such, how transferable is the existing evidence-base to UK or indeed European practice, how do 
single site reports reflect wider practice and what is the scope of direct patient care delivered by clinical 
pharmacy teams ? Although European publications on SCCP in critical care are on the increase [8, 10, 11, 15, 
16], variation in clinical pharmacy standards and services are pronounced [5, 17, 18]. The importance of SCCP 
services in critically ill patients are recognised in national UK intensive care standards [18]. These standards 
include recommendations for staff skill mix (pharmacist and pharmacy technicians) and recommends that 
clinical pharmacy services are best delivered using a team approach. More data is required to inform how these 
clinical pharmacy services should be configured and delivered to support resource decisions.  
 
The speciality of critical care and patient-related factors affect the types of interventions clinical pharmacist 
make [15]. In addition, the knowledge, skills and level of practice of the clinical pharmacist [19] is another 
important factor likely to affect the clinical impact of the direct patient care provided. Data on the clinical 
significance of these SCCP-led direct care activities need to be better described if we are to ascertain the true 
patient value of the services provided.      
 
In order to begin to answer some of these questions, we conducted a prospective multicentre service evaluation 
of clinical pharmacist interventions across UK intensive care units (ICU). The aim of the study was to describe, 
quantify and assess the clinical importance of direct patient care activities of critical care clinical pharmacy 
teams.   
 
 
Materials and methods 
 
 
Design 
 
This prospective observational study was conducted in 21 adult critical care units across the UK over a 14 day 
period from 5-18
th
 November 2012. A pilot test run was undertaken prior to this to test the data collection web 
portal and to support SCCP familiarity with the categories and methodology. All SCCP were members of the 
United Kingdom Clinical Pharmacy Association (UKCPA) Critical Care Group Expert Group. These members 
were the site co-ordinators of their base hospital’s pharmacy team. The study was deemed a clinical audit at 
University College London (UCL) and need for ethics committee approval was waived. It was consequently 
registered as a clinical audit at each participating site. 
 
 
Data collection 
 
At each CCU, every SCCP and pharmacy team member recorded their recommendations/interventions, which 
they provided as part of their existing role. Intervention episodes were recorded on the specifically created, 
password-protected web portal. All patient identifiable data was anonymised. The details recorded included a 
short description of the intervention, type of intervention, severity as decided by reporting pharmacist, whether 
the intervention was acted on (acceptance), method of communication back to CCU multidisciplinary team and 
whether the intervention lead to a positive or negative patient outcome. The primary medication that 
underpinned the intervention was classified by associated body-system, as defined by the British National 
Formulary . 
 
Activity data including time spent on clinical activities, number of patients seen and medication orders that were 
reviewed, was also entered on the portal 
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Interventions 
 
To explore the nature of the interventions made by clinical pharmacists, the number of interventions was 
quantified. To assess relevant denominators, the following data sets were recorded: the number of new 
prescriptions reviewed each day (on day 1, all prescriptions were regarded as new) and the number of patients 
drug charts reviewed. The type of intervention was characterised according to a previously used classification 
[20] . The CCU team would either accept’ or ‘reject’ the intervention or in some cases the changes would be 
self-prescribed by ‘independent prescribing pharmacists’. The incidence of these were recorded. 
 
Each intervention was categorised by the clinical pharmacist into one of three groups: [1] medication error, [2] 
optimisation or [3] consult. A medication error was defined as an error in the process of prescribing, dispensing, 
preparing, administering, monitoring or providing medicine advice, regardless of whether harm has occurred 
[21]. Optimisation was defined as a proactive contribution that sought to enhance patient care. A consult was 
defined as a reactive intervention in response to a request from member of the multidisciplinary team (MDT) for 
a SCCP review. 
 
Clinical pharmacists 
 
In the UK, a SCCP describes a practitioner who is working at advanced or mastery level, as defined by Royal 
Pharmaceutical Society Faculty of Advanced Practice [22].  Accreditation by the Faculty is based upon 
competency, skills and knowledge specific to the speciality of critical care. Certain teams were led by a 
consultant pharmacist which describes a practitioner working at mastery level with a consultant job plan. 
 
A ‘junior pharmacist’ is working at or below foundation level in critical care and would typically be working 
within a team lead by a SCCP.   
 
A number of pharmacists were accredited ‘independent pharmacy prescribers’ which allows them to prescribe 
within their sphere of competence, without co-signature by a medical practitioner. 
 
 
Clinical impact coding 
 
Each intervention was coded for clinical impact/importance to the patient. An established scale was used to code 
medication errors [21]. A bespoke optimisation and consult scale was created because a validated scale to cover 
this aspect of pharmaceutical care was not available. The new scale was based on the principles of categorised 
severity of drug related problems described in the literature [23, 24]. Participants were provided with examples 
of coding for typical interventions. The error coding was applied on the premise of what the potential 
consequence would be if the error had not been prevented by the pharmacist’s intervention. The optimisation 
and consult coding was ascribed on the basis of its potential clinical significance to the patient’s care. 
 
The individual clinical pharmacist recorded their own impact code. All the interventions were blind-coded by 
one of the principal investigators (SCCP RS) for the purposes of consistency. Where the codings matched, this 
was considered the final code. If there was a difference, the intervention was blind-coded by one of two 
investigators (consultant pharmacists RB and MT). Where two of the codes matched, this was considered the 
final code. If all three codes disagreed, then a critical care consultant physician (AJ) blind-coded the 
intervention and the final code was where two codes matched. This was deemed a pragmatic method to deal 
with the high number of interventions. 
 
 
Analysis 
 
The data from the web portal was downloaded and analysed using SPSS version 22 (IBM).  
 
 
 
 
Results 
 
Clinical pharmacy teams from twenty one critical care units participated. The demographics of the units and 
pharmacy teams are described in Table 1. The critical care units comprised of general or specialist intensive care 
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units (ICUs), high dependency units (HDUs including single organ support and post-operative care) and mixed 
ICU/HDUs. There were differences in the composition of the pharmacy teams in terms of pharmacist to patient 
ratio, pharmacist experience, independent prescriber status, team-members role and grading. There were 13 
independent pharmacist prescribers and 24 non-prescribing pharmacists in total. Some teams had a clinical 
pharmacy technician or a student on attachment and their role was focussed on medicine reconciliation. Only 
two of the units had any weekend proactive clinical pharmacy service, both of which were on Saturdays. Hence 
the vast majority of the interventions were made on weekdays.  
 
In total there were 3,390 interventions recorded in the 925 patients reviewed by the pharmacy teams, of whom at 
least one intervention was made in 774 patients (83.7%). Since 97% of these interventions occurred on 
weekdays, the following results concentrate on the weekdays when a full service was in place. There were 3,294 
interventions recorded in of 20,517 medication orders reviewed, equating to a rate of 1 intervention per 6 
(16.1%) medication orders reviewed. Of these 1393 (6.8%) were medication errors, 1693 (8.3%) were 
optimisations and 208 (1.0%) were consults. 2889 (87.7%) interventions were agreed with and actioned by the 
doctor or self-prescribed by the pharmacist. 6% of interventions were not accepted, whilst the remaining data 
was lost to follow-up (1.4%) or missing (5.1%). Over half (1956, 59.4%) of the interventions were discussed 
with the critical care team by the clinical pharmacist attending the bedside multidisciplinary ward round. In 
other cases the intervention were discussed with individual doctors, in a multidisciplinary handover meeting or 
were self-prescribed by independent pharmacist prescribers. The impact coding of the interventions made at 
weekdays are shown in Table 2. Of the medication errors, 19.0% were designated as ‘high’ impact had they 
been administered as prescribed and 42.6% were of ‘moderate’ impact. A similar pattern was seen with the 
optimisations with 19.0% ‘high’ and 48.3% of ‘moderate’ impact. Of the consults, 24.0% were ‘high’, 60.6% of 
‘moderate’ impact and 0.5% potentially averted a fatal consequence. 
 
The impact scores of the interventions of different types of pharmacy team members are shown in Figure 1. The 
interventions of the specialist, more experienced team members were of a higher impact score than the more 
junior pharmacy team members (Kruskal Wallis Test=154.9; p<0.0001). 
 
The reasons for the interventions are described in Figure 2. The dominant two categories were to optimise the 
effectiveness of, and to improve safety of the pharmacotherapy, accounting for 2,432 (73.8%) of all the 
interventions. The less frequent categories were: medicine reconciliation; conformity to guidelines,  
communication flow within the critical care team and primary teams and  infection control. 
 
Figure 3 describes the problem that the interventions addressed. The most common problem was adding or 
refining pharmacotherapy to optimally treat the patient. Approximately 15% of the interventions were to stop 
prescribed drug therapy that was no longer considered necessary. Other frequent interventions related to drug 
administration, medicines reconciliation, supra or sub-therapeutic drug doses, non-conformity to guidelines, 
monitoring of drug therapy, instigating supply alternatives to medicines that were unavailable, identifying and 
investigating adverse drug events, issues of intravenous compatibility and drug interactions. 
 
There was a statistically significant increased proportion of interventions on Mondays (24.1%) versus any other 
weekdays (range 17.0 to 21.0%) (CHI squared test p=0.01) 
 
More than 75% of the interventions were related broadly to central nervous system, cardiovascular, infection, 
gastrointestinal, nutrition and blood systems. Only a small proportion involved the respiratory system which 
contrasts to the general focus of medicine in critical care. 
 
 
Discussion 
 
To our knowledge, this is the first multi-centred study describing clinical pharmacist contribution to the care of 
the critically ill patient. Overall clinical pharmacists made interventions in almost 1 in 6 prescribed medications 
(16.1% of prescribed items) and more than 60% of the interventions were of at least moderate impact.  
Medication errors were found in 6.8% of all prescribed items, which is slightly lower than the 8.9% rate 
identified by the EQUIP study [25] which specifically examined prescribing error rates by medical staff in 
multi-site acute hospitals in the UK. 
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Unlike EQUIP; this study also uncovered a further 8.3% of prescriptions where clinical pharmacists made an 
optimisation intervention and another 1% of orders where a specific consult occurred, shedding more light on 
the extent of a pharmacists clinical interactions within this environment in the UK. 
 
In our study, ‘high impact’ interventions were made in 3.1% of prescriptions, compared with the reported rate of 
1.74% in EQUIP (which does not include optimisations and consults), whilst moderate impact interventions 
were made in 7.7% of prescriptions compared with 5.48% in EQUIP.  Many recommendations were made in 
EQUIP  including improving  the work environment, the use of standard medication charts and improving the 
undergraduate education of medical students, whilst acknowledging that the existing systems in place meant that 
many errors were intercepted by pharmacist before reaching the patient. These recommendations were made on 
the basis that errors were being predominantly made by junior doctors. Critical care is generally staffed by more 
experienced caregivers from the multi-disciplinary team (MDT) and whilst the EQUIP recommendation are still 
valid, we believe that further measures could be made to strengthen the existing systems for error detection and 
medication optimisation within critical care.  
 
The clinical pharmacists were closely integrated within the clinical teams, with nearly 60% participating on the 
MDT ward round and approximately 88% of interventions were accepted by the clinical team. The senior or 
consultant SCCP made interventions with a higher impact than non-specialist pharmacists. This confirms that 
the UK clinical pharmacist is a vital component of the critical care unit; senior (and consultant) SCCPs should 
be available to clinically review the more complex patient and train the MDT and junior colleague(s) [18]. 
 
The avoidance of  unnecessary iatrogenic harm is a key objective of patient safety measures in the acute patient 
setting [26]. Over a 2 week period, there were 1,393 reported medication errors in 395 patients at weekdays 
(result not shown). This corresponds with earlier studies confirming that the presence of a clinical pharmacist is 
an effective method for identifying and rectifying of medication errors. Only 2 of 21 units reported a weekend 
(Saturday service).  The higher proportion of interventions made on Mondays could be attributed to a lack of a 
clinical pharmacy service from the preceding weekend. The intervention rate was higher at the weekend with 
rate of 1 in 3 prescriptions [27]. Such data implies that clinical pharmacy services should be reviewed to ensure 
that every critically ill patient receives pharmaceutical care when needed; 7 days per week and perhaps 
ultimately 24/7; though the cost-effectiveness of this coverage would need to be explored. It seems counter 
intuitive to provide an intervention that improves prescribing safety or optimises therapy only on specific days 
of the week whilst the rest of critical care is delivered continuously. 
 
In Europe, many critical care units do not routinely receive clinical pharmacy services [5]. This is despite 
evidence that corroborates the important medication safety role of clinical pharmacists in European critical cares 
[8, 10]. In May 2014, new hospital pharmacy practice standards for Europe were agreed at an international 
summit in Brussels [28]. These standards were developed to ensure safe and effective medicine use is applied 
across European health systems. Whilst this study was undertaken in the UK where clinical pharmacy is fully 
integrated within the National Health Service (NHS). We believe this multi-site study of existing practice  
contributes to existing evidence and further supports the development of a European standard for the provision 
of clinical pharmacy services (including specialist services by SCCPs). In 2006, MacLaren et al, [12] reported 
on the clinical services provided by US critical care pharmacists at the time. The results of our study 
demonstrate further developments in the fundamental and desirable direct patient care clinical activities 
delivered by clinical pharmacy teams including SCCPs. 
 
The dominant two categories of clinical pharmacy intervention were to optimise the effectiveness and to 
improve safety of pharmacotherapy. This accounted for 73.8% of all reported interventions. Alongside 
prevention of iatrogenic harm; patient safety is paramount in critical care.  A gravely ill patient cannot actively 
participate in decisions on their pharmacotherapy. Thus it is essential that the MDT (nurse, pharmacist and 
doctor) ensures that the patient is safe and that their therapy is optimised for their needs (including taking 
account of their pharmacokinetic reserve). The investigators believe that the data from this study are an 
important addition to the existing literature and affirm the major role the clinical pharmacists and especially 
SCCPs have in delivering this goal.  
 
It is generally accepted that patients are at greater risk of harm on ‘step-down’ or transfer of care [29-31]. 
Medicine reconciliation is a recognised method of reducing the medication related harm [32, 33]. This study 
confirmed that medicines reconciliation was undertaken by the clinical pharmacist at all participating sites and 
which is recognised as core in the recently published UK critical care national standard.  
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There a number of limitations of this study: critical care units were not standardised and the study included all 
the patients on each CCU, which could include ICU, HDU and a number  patients were ready for ward care. 
Some of the  hospitals were treated as though they were one discrete ICU whereas others reported each critical 
care unit within a hospital group separately. The clinical interventions were self-reported by the SCCP which 
could introduce bias and potentially those interventions not accepted may have been less likely to be reported. 
Although this did not appear to be the case at the regular study meetings. The study was solely conducted in the 
UK, where clinical pharmacists are well established and integrated into critical care team. This may not be the 
case elsewhere. It is not known how many patients were admitted during the study period and were not seen by 
the pharmacy teams, e.g overnight and at weekends. Lastly, the impact coding was allocated on the basis of 
what may have happened if the intervention did not occur, introducing some subjectivity to the coding. We 
assert that this was partially  offset by a series of blinded multi-disciplinary assessors. 
 
Conclusion 
 
We have described a multi-centre study undertaken over a number of critical care units in the UK which 
identified the high frequency and clinical importance of medication interventions made by clinical pharmacists. 
These results underline the importance of the direct patient care clinical pharmacists, including SCCPs. The 
study also informs our understanding  on the difference between levels of clinical pharmacist, from junior to 
consultant SCCP and the likely clinical impact of their practice in improving patient safety and care. The 
medicines optimisations activities of clinical pharmacist further emphasise that clinical pharmacy is a 
fundamental component of critical care medicine across the UK and the wider healthcare community. 
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Table 1. Demographics 
 
Hospital  General/spe
cialised 
unit? 
Medical/su
rgical 
unit? 
Num
ber 
of 
beds 
Devel
oped 
team
 a
? 
Electro
nic 
prescrib
ing? 
Consult
ant 
pharma
cist? 
Accred
ited 
teachin
g unit? 
Week
end 
servic
e? 
How do 
pharmacist
s address 
interventio
ns? 
Addenbro
oke’s 
Hospital 
General Mixed 20 Yes No Yes Yes No Self-
prescribed 
FIFE 
Hospital 
General Mixed 9 No No No Yes No Bedside 
ward round 
Guy’s 
and St 
Thomas’ 
NHS 
Foundatio
n Trust 
General Mixed 80 Yes Yes Yes Yes Yes Other 
Newcastl
e Upon 
Tyne 
Hospital - 
Freeman 
Hospital 
Specialised Mixed 18 Yes Yes No Yes No Other 
Newcastl
e Upon 
Tyne 
Hospital - 
Royal 
Victoria 
Infirmary 
General Mixed 20 Yes Yes No Yes No Other 
Oxford 
Universit
y 
Hospitals 
General Mixed 18 Yes Yes Yes Yes No Individual 
feedback 
to junior 
doctors 
Portsmou
th 
Hospitals 
General Mixed 22 Yes Yes No Yes No Bedside 
ward round 
Royal 
Free 
Hospital 
General Mixed 31 Yes No No Yes No Bedside 
ward round 
Salford 
Royal 
Hospital 
Specialised Mixed 16 No Yes No Yes No Bedside 
ward round 
Sandwell 
and West 
Birmingh
am 
Hospital 
General Mixed 10 No No Yes Yes No Bedside 
ward round 
Northern 
General 
Hospital - 
General 
ICU 
General Mixed 16 Yes Yes Yes Yes Yes Multidiscip
linary team 
meeting 
Northern 
General 
Hospital 
General 
HDU 
General Mixed 16 Yes Yes Yes No Yes Multidiscip
linary team 
meeting 
AC
CE
PT
ED
 M
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Royal 
Hallamsh
ire 
Hospital 
General 
ICU/HD
U 
General Mixed 8 Yes Yes Yes No Yes Multidiscip
linary team 
meeting 
Royal 
Hallamsh
ire 
Hospital 
Neuroscie
nces 
ICU/HD
U 
Specialised Mixed 20 Yes No Yes Yes No Multidiscip
linary team 
meeting 
St 
Helen’s 
and 
Knowsley 
Teaching 
Hospital 
General Mixed 14 No No No Yes No Other 
Universit
y College 
London 
Hospitals 
General Mixed 35 Yes Yes No Yes No Multidiscip
linary team 
meeting 
Universit
y 
Hospital 
Birmingh
am 
General Mixed 18 No yes No Yes No Individual 
feedback 
to junior 
doctors 
Universit
y 
Hospitals 
Southamp
ton 
General Mixed 21 Yes No Yes Yes No Bedside 
ward round 
Western 
Infirmary 
Glasgow 
General Mixed 9 No Yes No Yes No Bedside 
ward round 
West 
Suffolk 
Hospitals 
General Mixed 9 No Yes No Yes No Bedside 
ward round 
Wrightin
gton 
Wigan 
and Leigh 
Hospital 
General Mixed 11 Yes No No Yes No Bedside 
ward round 
a
Developed team= defined as more than one pharmacist per team 
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Table 2. Impact coding of the interventions 
 
 Impact coding of the interventions 
Type of 
intervention 
Low impact Moderate impact High impact Life-saving Total 
Error 536 (16.3%, 38.5%) 593
 
(18.0%, 42.6%) 264
 
(8.0%, 19.0%) 0
 
(0.0%, 0.0%) 1,393 (42.3%) 
Optimisation 553 (16.8%, 32.7%) 818 (24.8%, 48.3%) 322 (9.8%, 19.0%) 0 (0.0%, 0.0%) 1,693 (51.4%) 
Consult 31 (0.9%, 14.9%) 126 (3.8%, 60.6%) 50 (1.5%, 24.0%) 1 (0.0%, 0.5%) 208 (6.3%) 
Total 1120 (34.0%) 1537 (46.7%) 636 (19.3%) 1 (0.0%) 3,294 (100%) 
In each case the first percentage is the percentage of total interventions 
The second percentage is the percentage of the type of intervention i.e. error, optmisation or consult. 
 
 
 
 
 
